Equities research analysts expect Mediwound Ltd (NASDAQ:MDWD) to announce $650,000.00 in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Mediwound’s earnings, with the highest sales estimate coming in at $700,000.00 and the lowest estimate coming in at $540,000.00. Mediwound reported sales of $430,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 51.2%. The company is scheduled to announce its next earnings report on Tuesday, February 20th.
On average, analysts expect that Mediwound will report full-year sales of $650,000.00 for the current fiscal year, with estimates ranging from $2.51 million to $2.61 million. For the next financial year, analysts expect that the company will post sales of $5.93 million per share, with estimates ranging from $3.80 million to $9.83 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Mediwound.
Mediwound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Mediwound had a negative net margin of 904.26% and a negative return on equity of 246.58%.
Shares of Mediwound (NASDAQ MDWD) opened at $4.20 on Friday. The company has a market cap of $109.54, a P/E ratio of -4.29 and a beta of 0.01. Mediwound has a 1-year low of $3.56 and a 1-year high of $8.25.
Several institutional investors and hedge funds have recently added to or reduced their stakes in MDWD. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Mediwound by 5,084.4% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 754,434 shares of the biopharmaceutical company’s stock valued at $3,357,000 after purchasing an additional 739,882 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Mediwound during the 3rd quarter valued at $2,140,000. Nationwide Fund Advisors purchased a new position in shares of Mediwound during the 3rd quarter valued at $1,538,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Mediwound by 9.5% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock valued at $11,882,000 after purchasing an additional 192,860 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Mediwound by 84.6% during the 4th quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock valued at $450,000 after purchasing an additional 46,366 shares in the last quarter. Hedge funds and other institutional investors own 29.46% of the company’s stock.
Mediwound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.